Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 1/20 | 0.46 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3857333 | 0.87 | EIF4EBP1 (0.38) | METGRM4SMN1; SMN2MAPTALK | |
| SCHEMBL3860435 | 0.86 | MET (0.49) | MET | |
| SCHEMBL13896319 | 0.79 | MET (0.57) | METKMT2APOLB | |
| SCHEMBL3862898 | 0.71 | MET (0.58) | METGRM4KCNH2 | |
| SCHEMBL3861949 | 0.71 | MET (0.49) | MET | |
| SCHEMBL13896313 | 0.71 | MET (0.50) | MET | |
| SCHEMBL3865465 | 0.70 | LTA4H (0.40) | KCNH2HRH3 | |
| SCHEMBL3859168 | 0.70 | LTA4H (0.47) | KCNH2HRH3 | |
| SCHEMBL3857614 | 0.70 | MET (0.42) | METGRM4SMN1; SMN2MAPTKMT2A | |
| SCHEMBL4892876 | 0.69 | MET (0.56) | MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8314087-B2 | Nitrogen-containing heterocyclyl ketones and methods of use | AMGEN INC. (US) | 2012-11-20 | — | — | US | disclosed |
| EP-2114898-A2 | NITROGEN-CONTAINING HETEROCYCLYL KETONES AND THEIR USE AS C-MET INHIBITORS | Amgen Inc. (US) | 2009-11-11 | — | — | EP | disclosed |
| US-20080280917-A1 | Nitrogen-Containing heterocyclyl ketones and methods of use | AMGEN INC. (US) | 2008-11-13 | — | — | US | disclosed |
| WO-2008103277-A2 | NITROGEN-CONTAINING HETEROCYCLYL KETONES AND THEIR USE AS C-MET INHIBITORS | AMGEN INC. (US) | 2008-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280917-A1 | Nitrogen-Containing heterocyclyl ketones and methods of use | HGF, HGFAC, MET | MET 3/4885GRM4 3718/4885SMN1; SMN2 864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.